520 POSTER Marked inhibition of tumor growth, MMP secretion and invasion by a nutrient mixture on head and neck squamous carcinoma cell line FaDu: in vitro and in vivo studies

2006 ◽  
Vol 4 (12) ◽  
pp. 158
Author(s):  
M.W. Roomi ◽  
V. Ivanov ◽  
A. Niedzwiecki ◽  
M. Rath
1988 ◽  
Vol 98 (6) ◽  
pp. 552-557 ◽  
Author(s):  
Thomas P.U. Wustrow ◽  
Alexander Raffael ◽  
Günter Valet

Squamous cell carcinomas of the head and neck consist of heterogeneous cell populations. The purpose of the present study was to Investigate whether established cell lines from human head and neck cancers under chemotherapy behaved similarly to tumors in patients during in vivo treatment. This Is of Interest in terms of improvements of chemotherapeutic protocols and understanding of the mechanisms of cytotoxic drug resistance. Permanent squamous carcinoma cell lines of the larynx (HLaC 78, 79), parotid gland (HPaC 79), tongue (SCC-15, SCC-25), hypopharynx (FaDu), and tumor lines with different histology and origin, as mucoepidermoid cancer cells of the submandibular gland (A 253), Epstein-Barr virus-infected human B cells (BC-1) and mouse fibroblasts (3T3) were Incubated with chemotherapeutic drugs for 1 to 4 days at 37° C. Despite the microscopic similarities to patient carcinomas, cancer cell lines of the head and neck showed different susceptibilities to cell kill mediated by chemotherapeutic drugs, as compared to in vivo therapeutic results with patients. The nonsquamous carcinoma lines demonstrated high chemosensitive responses after incubation with daunorubicin, cyclophosphamide, dactinomycin, vincristine, and aclarubicin. Surprisingly, only low cell killing rates in squamous carcinoma cell lines were observed after incubation with chemotherapeutic agents such as cis-platinum, 5-fluorouracil, methotrexate, or bleomycin, which are most commonly used for head and neck cancers. The results show that cytotoxic drug action on in vitro cultured squamous carcinoma cell lines of the head and neck is not representative for the in vivo responses of patient tumors. The cell lines are, however, of potential value for evaluation of cell biochemical changes associated with cytotoxic drug resistance.


1992 ◽  
Vol 51 (6) ◽  
pp. 909-914 ◽  
Author(s):  
B. F. A. M. van der Laan ◽  
G. Jansen ◽  
G. A. M. Kathmann ◽  
G. R. Westerhof ◽  
J. H. Schornagel ◽  
...  

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A627-A627
Author(s):  
Cleopatra Rutihinda ◽  
Leanié Moreau ◽  
Safia Chelighem ◽  
Ayman Oweida

BackgroundRadiotherapy (RT) is commonly used to treat solid tumors but its efficacy varies widely. In non-virally driven head and neck cancer (HNC), radioresistance is responsible for most cases of tumor progression and tumor recurrence. The combination of RT and immunotherapy (IT), in the form of anti-PD-1/PD-L1, improved survival for a minority of patients with tumors that have pre-existing immunity or which are susceptible to RT-induced tumor immunity. In contrast, tumors with an immunosuppressive microenvironment show resistance to RT and/or IT. Regulatory T cells (Tregs) have been shown to be prevalent in HNC tumors and can promote treatment resistance. We identified the chemokine, CCL20 as a factor that can promote infiltration of Tregs into HNC tumors. CCL20 is secreted by the cancer cell and binds to its sole receptor, CCR6, expressed on Tregs. We therefore hypothesized that radiation induces CCL20 secretion resulting in infiltration of Tregs and radioresistance. We further hypothesized that blocking CCL20 in HNCs where CCL20 is induced in response to RT can decrease tumor growth.MethodsHuman and murine HNC cell lines (SCC9, Cal27, MOC1, MOC2) were irradiated at doses of 2Gy or 10Gy. Conditioned media (CM), RNA and protein were obtained 24h and 72h after radiation. The concentration of CCL20 was analyzed using a chemokine array. Gene expression was determined using qPCR. For in vivo studies, the MOC2 cell line was used. Mice were inoculated in the buccal cavity. Neutralizing CCL20 antibody was administered alone and in combination with RT. Blood samples were collected before and after RT for analysis of serum levels of CCL20.ResultsGene expression analysis showed that Cal27 and MOC2 tumors had a gene signature associated with immune-suppression and Treg cell infiltration. In contrast, SCC9 and MOC1 tumors displayed a gene signature associated with an inflamed microenvironment. In vitro, radiation induced a significant increase in CCL20 gene expression and secreted CCL20 in Cal27 and MOC2 cells relative to control. In contrast, MOC1 and SCC9 did not show a significant increase in CCL20 after radiation. In vivo, inhibition of CCL20 decreased tumor growth compared to control in MOC2 tumors. The combination of RT and anti-CCL20 showed a significant decrease in tumor growth compared to RT alone.ConclusionsCollectively, our data suggest that radiation promotes the induction of CCL20 in tumors with immune-suppressive mechanisms and inhibition of CCL20 can enhance the response to RT.Ethics ApprovalAll animal studies were conducted in accordance with the animal protection and ethics committee of the faculty of medicine at Universite de Sherbrooke (Le Comité facultaire de protection des animaux). Protocol #: 2019–2333.


2019 ◽  
Vol 65 (5) ◽  
pp. 760-765
Author(s):  
Margarita Tyndyk ◽  
Irina Popovich ◽  
A. Malek ◽  
R. Samsonov ◽  
N. Germanov ◽  
...  

The paper presents the results of the research on the antitumor activity of a new drug - atomic clusters of silver (ACS), the colloidal solution of nanostructured silver bisilicate Ag6Si2O7 with particles size of 1-2 nm in deionized water. In vitro studies to evaluate the effect of various ACS concentrations in human tumor cells cultures (breast cancer, colon carcinoma and prostate cancer) were conducted. The highest antitumor activity of ACS was observed in dilutions from 2.7 mg/l to 5.1 mg/l, resulting in the death of tumor cells in all studied cell cultures. In vivo experiments on transplanted Ehrlich carcinoma model in mice consuming 0.75 mg/kg ACS with drinking water revealed significant inhibition of tumor growth since the 14th day of experiment (maximally by 52% on the 28th day, p < 0.05) in comparison with control. Subcutaneous injections of 2.5 mg/kg ACS inhibited Ehrlich's tumor growth on the 7th and 10th days of the experiment (p < 0.05) as compared to control.


Life Sciences ◽  
2021 ◽  
Vol 278 ◽  
pp. 119541
Author(s):  
Aysegul Gorur ◽  
Miguel Patiño ◽  
Hideaki Takahashi ◽  
German Corrales ◽  
Curtis R. Pickering ◽  
...  

2018 ◽  
Vol Volume 13 ◽  
pp. 107-111 ◽  
Author(s):  
Manjri Singh ◽  
Parul Gupta ◽  
Richa Baronia ◽  
Priti Singh ◽  
Stalin Karuppiah ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document